|
Active Pharmaceutical Ingredient Of Ultram
The Tenuate drug
is generally prescribed for the suppression
of appetite, and is used in conjunction with
an overall diet plan and an exercise program
to reduce weight and manage obesity.
A brief on the directions of Tenuate
drug reveals that this medication must be taken
in an empty stomach, and preferably one-half
hour prior to having breakfast.
Due to the feelings of drowsiness
and sleeplessness, it is generally advised that
the drug should not be taken during later part
of the day. Specific instructions from the consulting
physician is the best strategy, and one should
not take more than the prescribed dosage, and
for a period specifically directed by the consulting
physician.
Some of the side effects associated
with the use of Tenuate drug include dry mouth,
sleeplessness, irritability, stomach upset or
constipation in the first few days after commencing
Tenuate. It is generally advised that if either
of these symptoms persist, or become bothersome,
the consulting physician or the area doctor
must be immediately notified.
As to the brief on some of the
precautions on the use of Tenuate drug for managing
obesity and reducing weight, it is generally
advised that prior conditions and ailments of
high blood pressure, heart diseases, overactive
thyroid, glaucoma, diabetes or emotional problems.
Furthermore, women who are pregnant,
and those breast-feeding their infants are also
advised against the use of Tenuate due to its
severe side effects. The use of Tenuate is also
not recommended for those using alcohol or is
know abusers of drugs. Tenuate is also not recommended
for children.
As a note of precaution,
it is suggested that since Tenuate is an appetite
suppressant and is not a substitute for proper
diet, the best results are obtained through
a proper diet plan and an exercise program,
yet without the assistance or combination of
other drugs. |
|
| Tramadol HCl (Ultram,
Ortho-McNeil), is a centrally acting, synthetic,
binary analgesic. The drug was approved by the
FDA March 7, 1995, and is indicated for the
management of moderate to moderately severe
pain.
The drug has been used in more
than 39 million patients in 70 countries since
1977. Tile FDA has not classified tramadol as
a controlled substance.
Tramadol-associated adverse effects have been
reported. Adverse effects occurred in approximately
15% of patients who received up to 400 mg/day.
The adverse reactions were similar
to those reported with opioids. The most prominent
adverse effects involve the central nervous
system and the gastrointestinal tract. Common
adverse effects reported in the trials reviewed
in this Focus include nausea, vomiting, dizziness,
somnolence, drowsiness, constipation, restlessness,
sweating, headache, and palpitations.
Tramadol's potential for chemical psychological
dependency is apparent low. A review of the
foreign clinical experience revealed only 152
cases in 39 million patients.The explanation
for this low risk is due to the delayed mu opioids
effect of the active M1 metabolite.
Tramadol should be used with extreme caution
in patients receiving monoamine oxidase inhibitors.
Caution should also be exercised and a reduced
dose given when tramadol is administered with
alcohol, sedative hypnotics, opioids analgesics,
anesthetic agents, or other agents that act
upon the central nervous system (CNS).
Likewise, CNS-related adverse effects
may arise if over-the-counter cold, sleep, and
analgesic medications are taken with tramadol.
Respiratory depression may occur if the recommended
dosage is consistently exceeded or if another
centrally acting depressant drug (eg, alcohol,
anesthesia) is given concurrently.
|
|
|
|
|
